Free Trial

Talphera (TLPH) Competitors

Talphera logo
$1.17 -0.06 (-4.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 +0.09 (+7.61%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TLPH vs. CRBU, BDTX, TRDA, NLTX, EPRX, CLLS, CABA, TNXP, BIOA, and SLS

Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), Entrada Therapeutics (TRDA), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Cellectis (CLLS), Cabaletta Bio (CABA), Tonix Pharmaceuticals (TNXP), BioAge Labs (BIOA), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

Talphera vs. Its Competitors

Talphera (NASDAQ:TLPH) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Talphera has higher earnings, but lower revenue than Caribou Biosciences. Talphera is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talphera$650K82.06-$13M-$0.40-2.93
Caribou Biosciences$9.99M22.18-$149.10M-$1.78-1.34

Talphera currently has a consensus price target of $5.00, suggesting a potential upside of 327.35%. Caribou Biosciences has a consensus price target of $6.67, suggesting a potential upside of 180.11%. Given Talphera's stronger consensus rating and higher probable upside, equities analysts clearly believe Talphera is more favorable than Caribou Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.00
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

37.7% of Talphera shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 5.7% of Talphera shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Talphera has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.

Talphera has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. Caribou Biosciences' return on equity of -62.35% beat Talphera's return on equity.

Company Net Margins Return on Equity Return on Assets
TalpheraN/A -152.38% -64.32%
Caribou Biosciences -1,800.93%-62.35%-49.65%

In the previous week, Talphera had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Talphera and 3 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.83 beat Talphera's score of 0.77 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Talphera
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Caribou Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Caribou Biosciences beats Talphera on 9 of the 17 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLPH vs. The Competition

MetricTalpheraMED IndustryMedical SectorNASDAQ Exchange
Market Cap$56.07M$2.61B$6.05B$10.30B
Dividend YieldN/A57.78%5.73%4.82%
P/E Ratio-2.9222.5785.3127.10
Price / Sales82.06755.26601.46133.29
Price / CashN/A26.3325.7730.18
Price / Book2.495.3512.676.69
Net Income-$13M$33.06M$3.32B$276.55M
7 Day Performance6.36%0.94%-0.44%-1.14%
1 Month Performance24.47%9.75%8.72%6.50%
1 Year Performance48.10%-0.52%75.69%33.95%

Talphera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLPH
Talphera
1.7541 of 5 stars
$1.17
-4.9%
$5.00
+327.4%
+55.7%$56.07M$650K-2.9219Gap Up
CRBU
Caribou Biosciences
2.185 of 5 stars
$2.43
+3.8%
$6.67
+174.3%
+31.1%$226.28M$9.99M-1.37100
BDTX
Black Diamond Therapeutics
3.5207 of 5 stars
$3.91
-0.3%
$11.00
+181.3%
+22.8%$222.62M$70M17.0090Positive News
TRDA
Entrada Therapeutics
2.6699 of 5 stars
$5.85
-1.2%
$25.67
+338.7%
-63.7%$222.53M$210.78M-3.29110Positive News
NLTX
Neoleukin Therapeutics
N/A$23.09
+3.4%
N/A-38.9%$217MN/A-7.4290High Trading Volume
EPRX
Eupraxia Pharmaceuticals
2.7267 of 5 stars
$6.02
+0.7%
$11.00
+82.7%
+152.9%$216.49MN/A-7.0829
CLLS
Cellectis
0.6543 of 5 stars
$3.82
+8.2%
$4.00
+4.7%
+101.0%$212.33M$56.30M-4.66290Gap Up
CABA
Cabaletta Bio
2.9702 of 5 stars
$2.32
-4.9%
$14.50
+525.0%
-44.9%$212.20MN/A-0.8650Analyst Forecast
Gap Up
TNXP
Tonix Pharmaceuticals
2.6643 of 5 stars
$23.00
-5.0%
$70.00
+204.3%
+43.6%$201.71M$10.09M-0.5850Gap Down
BIOA
BioAge Labs
0.182 of 5 stars
$5.60
-0.5%
N/AN/A$200.76MN/A0.00N/A
SLS
SELLAS Life Sciences Group
1.9702 of 5 stars
$1.90
+0.5%
$7.00
+268.4%
+54.0%$200.07M$1M-5.9410News Coverage

Related Companies and Tools


This page (NASDAQ:TLPH) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners